7th May 2026 – Intravitreal injection of 2 mg Yesafili^TM (Biocon Biologics, Ltd., India), an anti-vascular endothelial growth factor (anti-VEGF) biosimilar of aflibercept, was performed for the first time at the Department of Ophthalmology, Faculty of Medicine, 集美麻豆 on 1 April 2026 by the Vitreoretinal 1 (Pink) team.

The injection was administered to a 63-year-old Chinese gentleman with branch retinal vein occlusion (BRVO) (stroke involving a branch of the main retinal vein) and refractory macular oedema (swelling in the centre of the retina nerve) in his right eye. He had been receiving various anti-VEGF agents over the preceding four years. His presenting complaint was central blurring of vision, with a best-corrected visual acuity of 6/9. Examination of the right eye retina revealed bleeding into a sector of the nerve (along the inferotemporal arcade) with involvement of the most central area (fovea). Optical coherence tomography (OCT) demonstrated multiple areas of fluid in the retinal layers (IRF) and under the retina i.e., subretinal fluid (SRF) involving the fovea, with increased central retina thickness (Figure 1). In view of persistent fluid and suboptimal treatment response, following discussion with the patient on the cost and benefit, Yesafili^TM was selected with the aim of improving visual acuity, resolving IRF and SRF on OCT, and achieving a longer treatment interval.

The intravitreal injection was performed by Dr. Yap Jin Yi, Vitreoretinal Fellow at Hospital Canselor Tuanku Muhriz (HCTM) @ 集美麻豆 (Figure 2). The procedure was carried out under topical anaesthesia using a sterile technique. The injection was administered 4 mm posterior to the cornea limbus, delivering 2 mg (0.05 ml) of Yesafili^TM into the vitreous cavity via the pars planar. The procedure was uneventful. At one month post-injection, OCT demonstrated resolution of intraretinal fluid (IRF) and subretinal fluid (SRF), with restoration of the foveal contour (Figure 3) and corresponding improvement in visual symptoms.

Yesafili^TM is a vascular endothelial growth factor (VEGF) inhibitor and biosimilar to reference aflibercept. It contains aflibercept as its active substance, acting as a fusion protein that competitively binds VEGF-A and placental growth factor with greater affinity than their native receptors, thereby blocking the activation of VEGF signalling pathways that drive pathological angiogenesis and vascular leakage.

A biosimilar is a biological product that is highly similar to an approved reference drug in terms of its chemical, physical, and biological characteristics. Yesafili^TM received FDA approval in May 2024 for the treatment of diabetic macular edema, neovascular age-related macular degeneration, diabetic retinopathy, macular edema following retinal vein occlusion and retinopathy of prematurity.

Multiple studies have demonstrated clinical equivalence of Yesafili^TM to the reference aflibercept 2mg in terms of efficacy, safety, and pharmacokinetics (1-4). In addition, as with other biosimilars, it offers the potential for reduced treatment costs. Offering this biosimilar agent to Malaysian patients, as per indications will broaden therapeutic options not only targeting improved visual outcomes and a longer treatment interval, but also reducing the financial burden of treatment.

Figure 1. OCT image prior to intravitreal injection of Yesafili^TM, showing persistent intraretinal fluid (IRF, orange arrow) and subretinal fluid (SRF, blue arrow)

Figure 2. Intravitreal injection of Yesafili^TM performed by Dr. Yap Jin Yi at the procedure room of Eye Clinic, HCTM

Figure 3. OCT image one month following intravitreal injection of Yesafili, demonstrating resolution of intraretinal fluid (IRF) and subretinal fluid (SRF) with restoration of the foveal contour.

Reported by:

Dr. Triwijayanti

International fellow (Vitreoretina), Department of Ophthalmology, Faculty of Medicine, 集美麻豆

& Prof. Dr. Mae-Lynn Catherine Bastion

Senior Consultant Ophthalmologist, Department of Ophthalmology, Faculty of Medicine, 集美麻豆

2. Aljuhani HS, hubyani RA, Qedir J., Efficacy and Safety of Aflibercept Biosimilars Relative to Refernce Aflibercept Therapy for Neovascular Age Related Macular Degeneration: A Systemic Review and Meta-Analysis. Clin Ophthalmol.2025 Jun 19;19:1911鈥�1918. doi:聽
3. Delaney A, Kaiser PK. The Impact Potential of Aflibercept Bisimilars. Ann Eye Sci. 2025;10:33 doi:10.21037/aes-24-33
4. European Medicines Agency. Yesafili(aflibercept): Summary of Product Cahracteristics. https://www.ema.europa.eu/en/documents/product-information/yesafili-epar-product-information_en.pdf

The post First intravitreal injection of Aflibercept 2 mg (Yesafili) at the Department of Ophthalmology, 集美麻豆 appeared first on Jabatan Oftalmologi Fakulti Perubatan.

Pemeriksaan mata asas

Booth pameran berkaitan ubat titis air mata untuk mata kering

Jualan cermin mata oleh booth kedai cermin mata dan khidmat nasihat ralat refraksi oleh Pegawai Optometri bagi tujuan Tuntutan Alat Optik

Link penyertaan:

The post Hari Terbuka Saringan Mata Warga 集美麻豆 2026 appeared first on Jabatan Oftalmologi Fakulti Perubatan.

The post Majlis Menandatangani Surat Hasrat (LOI) Fakulti Perubatan 集美麻豆 & Brill International. appeared first on Jabatan Oftalmologi Fakulti Perubatan.

The post Sambutan Hari Retina dan Hari Penglihatan Sedunia 2025 appeared first on Jabatan Oftalmologi Fakulti Perubatan.

Prof. Dr. Mae-Lynn Catherine Bastion & Dr. Atikah binti Asini

Penerima Pingat Emas 鈥� Excellence Award bagi Penyelidikan dan Penerbitan

Prof. Dr. Norshamsiah Md. Din & Dr. Nurshazwani Ab Rahman

Penerima Pingat Perak 鈥� Excellence Award bagi Penyelidikan dan Penerbitan

Dr. Yap Jin Yi

Penerima Pingat Gangsa 鈥� Excellence Award bagi Penyelidikan dan Penerbitan

Dr. Wan Nur Najwa

Anugerah Pelajar Terbaik bagi Pelajar Pascasiswazah (Peperiksaan Bahagian I)

.

The post Anugerah di COAMM Scientific Congress & Graduation Ceremony 2025 appeared first on Jabatan Oftalmologi Fakulti Perubatan.

Syabas diucapkan kepada para pemenang dari Jabatan Oftalmologi, Fakulti Perubatan 集美麻豆 atas pencapaian cemerlang sempena Malaysian Ophthalmology Scientific Congress (MOSC) 2025 yang telah berlangsung di Berjaya Times Square Hotel, Kuala Lumpur pada 25鈥�27 April 2025.

Antara kejayaan membanggakan termasuk:

Champion of Intervarsity Quiz 2025 鈥� The Eyedol Minds

Best EPoster Award – Dr. Nurul Ibtisam Mohammad

Best Free Paper Award – Dr. Giovani Faustine

Bronze Award for Kahoot Quiz – Dr. Bee See Yee

MSO (Malaysian Society of Ophthalmology) Service Award) – Prof. Dr. Mae-Lynn Catherine Bastion

The post TAHNIAH KEPADA PARA PEMENANG DI MALAYSIAN OPHTHALMOLOGY SCIENTIFIC CONGRESS (MOSC) 2025 appeared first on Jabatan Oftalmologi Fakulti Perubatan.

The post Tahniah: Anugerah Pengiktirafan Penyelidikan Gegar Gamat! appeared first on Jabatan Oftalmologi Fakulti Perubatan.

The post PINGAT EMAS HARI PENYELIDIKAN & INOVASI 2025 appeared first on Jabatan Oftalmologi Fakulti Perubatan.